UNSPSC 51285202: Epiroprim

This classification denotes a folate antagonist and antiprotozoal agent with the molecular structure C19H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 9G69D95443 chemically known as 2,4-diamino-5-(3,5-diethoxy-4-pyrrol-1-ylbenzyl)pyrimidine, but more commonly known as epiroprim, which bears US NIH Compound Identifier 68916. European Medicines Agency schedules Epiroprim in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06570MIG.

The term EPIROPRIM is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 35, no. 5 1981, list 21).

UNSPSC 51285202 Epiroprim is a Commodity code that in practice covers pharmaceutical products supplied through state and local procurement channels, though recent activity shows the code is being applied inconsistently to orders for unrelated medications and medical supplies. State and local health departments and county public health authorities issue these procurements, typically through cooperative purchasing consortia or direct IFB processes. The Illinois Department of Public Health used the code in a piggyback pharmaceutical warehouse order through the MMCAP Infuse consortium awarded to Chartwell Rx LLC on August 28, 2026, though that contract covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride rather than epiroprim. Seminole County, Florida similarly tagged a procurement under this code for Naloxone and Safe Drug Deactivation Systems, reflecting a broader pattern of taxonomy misalignment across state and local buyers. The code shows limited recent activity aligned to its nominal scope.

Geographic activity appears concentrated in Florida and Illinois based on the two recent opportunities in the source. The Illinois Department of Public Health awarded a $2,999,999.11 contract over 12 months plus two renewal years through an IFB process for pharmaceutical warehouse supply, with initial response due September 11, 2026. Seminole County, Florida issued an IFB on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. Neither procurement plainly matches epiroprim as a pharmaceutical product category, signaling potential miscoding in state and local procurement databases.